Integrated Analysis of Mismatch Repair System in Malignant Astrocytomas

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Rodríguez Hernández, Irene ^a,b   Garcia, Juan Luis ^b,c   Santos Briz, Angel ^b,d   Hernández Laín, Aurelio ^e   González Valero, Jose María ^b,c   Gómez Moreta, Juan Antonio ^d   Toldos González, Oscar ^e   Cruz, Juan Jesús ^b,d   Martin Vallejo, Javier ^a   González Sarmiento, Rogelio ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b CSIC   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GLIOBLASTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MISMATCH REPAIR GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ASTROCYTOMA; COHORT STUDIES; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884488060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076401     Document Type: Article

References (52)

1. Ohgaki H, Kleihues P, (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489. PubMed: 15977639.
2. Wehming FM, Wiese B, Nakamura M, Bremer M, Karstens JH, et al. (2012) Malignant glioma grade 3 and 4: How relevant is timing of radiotherapy? Clin Neurol Neurosurg 114: 617-621. doi:10.1016/j.clineuro.2011.12.024. PubMed: 22244251.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466. doi:10.1016/S1470-2045(09)70025-7. PubMed: 19269895.
4. Ohgaki H, (2009) Epidemiology of brain tumors. Methods Mol Biol 472: 323-342. doi:10.1007/978-1-60327-492-0_14. PubMed: 19107440.
5. Wen PY, Kesari S, (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507. doi:10.1056/NEJMra0708126. PubMed: 18669428.
6. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024. doi:10.1056/NEJMoa051918. PubMed: 16282176.
7. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773. doi:10.1056/NEJMoa0808710. PubMed: 19228619.
8. The Cancer Genome Atlas (TCGA) Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
9. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev Neurol 6: 39-51. doi:10.1038/nrneurol.2009.197.
10. Huse JT, Holland EC, (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331. doi:10.1038/nrc2818. PubMed: 20414201.
11. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, et al. (2004) 2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268. doi:10.1093/jnci/djh034. PubMed: 14970275.
12. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, et al. (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123: 444-449. doi:10.1002/ijc.23508. PubMed: 18398828.
13. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, et al. (2009) Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 10: 400-408. doi:10.1016/S1470-2045(09)70041-5. PubMed: 19341971.
14. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, et al. (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76: 1-18. doi:10.1111/j.1399-0004.2009.01230.x. PubMed: 19659756.
15. Peltomäki P, (2005) Lynch syndrome genes. Fam Cancer 4: 227-232. doi:10.1007/s10689-004-7993-0. PubMed: 16136382.
16. Kastrinos F, Syngal S, (2012) Screening Patients With Colorectal Cancer for Lynch Syndrome: What Are We Waiting For? J Clin Oncol 30: 1024-1027. doi:10.1200/JCO.2011.40.7171. PubMed: 22355054.
17. Allan JM, Shorto J, Adlard J, Bury J, Coggins R, et al. (2008) MLH1-93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 123: 2456-2459. doi:10.1002/ijc.23770. PubMed: 18712731.
18. Mrkonjic M, Roslin NM, Greenwood CM, Raptis S, Pollett A, et al. (2010) Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer. PLOS ONE 5: e13314. doi:10.1371/journal.pone.0013314. PubMed: 20967208.
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. doi:10.1007/s00401-007-0243-4. PubMed: 17618441.
20. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, et al. (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065. doi:10.1038/labinvest.3700664. PubMed: 17700563.
21. Capel E, Fléjou JF, Hamelin R, (2007) Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis. Oncogene 26: 7596-7600. doi:10.1038/sj.onc.1210581. PubMed: 17546041.
22. Schleinitz D, Distefano JK, Kovacs P, (2011) Targeted SNP genotyping using the TaqMan(R) assay. Methods Mol Biol 700: 77-87. doi:10.1007/978-1-61737-954-3_6. PubMed: 21204028.
23. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, et al. (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257. PubMed: 9823339.
24. Ganguly A, Rock MJ, Prockop DJ, (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A 90: 10325-10329. doi:10.1073/pnas.90.21.10325. PubMed: 8234293.
25. Barnetson RA, Cartwright N, van Vliet A, Haq N, Drew K, et al. (2008) Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. Hum Mutat 29: 367-374. doi:10.1002/humu.20635. PubMed: 18033691.
26. Belvederesi L, Bianchi F, Loretelli C, Gagliardini D, Galizia E, et al. (2006) Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. Eur J Hum Genet 14: 853-859. doi:10.1038/sj.ejhg.5201628. PubMed: 16724012.
27. Caldes T, Godino J, de la Hoya M, Garcia Carbonero I, Perez Segura P, et al. (2002) Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain. Int J Cancer 98: 774-779. doi:10.1002/ijc.10240. PubMed: 11920650.
28. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, et al. (2012) Primary brain tumours in adults. Lancet 379: 1984-1996. doi:10.1016/S0140-6736(11)61346-9. PubMed: 22510398.
29. Hussein MR, El-Ghorori RM, El-Rahman YG, (2006) Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas. Int J Exp Pathol 87: 297-306. doi:10.1111/j.1365-2613.2006.00482.x. PubMed: 16875495.
30. Srivastava T, Chattopadhyay P, Mahapatra AK, Sarkar C, Sinha S, (2004) Increased hMSH2 protein expression in glioblastoma multiforme. J Neuro Oncol 66: 51-57. doi:10.1023/B:NEON.0000013482.99032.b0. PubMed: 15015769.
31. Castrilli G, Fabiano A, La Torre G, Marigo L, Piantelli C, et al. (2002) Expression of hMSH2 and hMLH1 proteins of the human DNA mismatch repair system in salivary gland tumors. J Oral Pathol Med 31: 234-238. doi:10.1034/j.1600-0714.2002.310407.x. PubMed: 12076327.
32. Rass K, Gutwein P, Welter C, Meineke V, Tilgen W, et al. (2001) DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. Histochem J 33: 459-467. doi:10.1023/A:1014472314354. PubMed: 11931386.
33. Esteller M, (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16Spec No 1: R50-59. PubMed: 17613547.
34. Arita M, Zhong X, Min Z, Hemmi H, Shimatake H, (2003) Multiple sites required for expression in 5'-flanking region of the hMLH1 gene. Gene 306: 57-65. doi:10.1016/S0378-1119(03)00385-8. PubMed: 12657467.
35. Chen H, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, et al. (2007) Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 120: 1684-1688. doi:10.1002/ijc.22406. PubMed: 17230510.
36. Lee KM, Choi JY, Kang C, Kang CP, Park SK, et al. (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 11: 4620-4626. doi:10.1158/1078-0432.CCR-04-2534. PubMed: 15958648.
37. Park SH, Lee GY, Jeon HS, Lee SJ, Kim KM, et al. (2004) 93G-- A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 112: 678-682. doi:10.1002/ijc.20359. PubMed: 15382050.
38. Eckert A, Kloor M, Giersch A, Ahmadi R, Herold-Mende C, et al. (2007) Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol 17: 146-150. doi:10.1111/j.1750-3639.2007.00049.x. PubMed: 17388945.
39. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, et al. (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129: 659-670. doi:10.1002/ijc.26083. PubMed: 21425258.
40. Viana-Pereira M, Lee A, Popov S, Bax DA, Al-Sarraj S, et al. (2011) Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. PLOS ONE 6: e20588. doi:10.1371/journal.pone.0020588. PubMed: 21637783.
41. Martinez R, Schackert HK, Appelt H, Plaschke J, Baretton G, et al. (2005) Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol 131: 87-93. doi:10.1007/s00432-004-0592-5. PubMed: 15672285.
42. Shah SN, Hile SE, Eckert KA, (2010) Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes. Cancer Res 70: 431-435. doi:10.1158/1538-7445.AM10-431. PubMed: 20068152.
43. Alldinger I, Schaefer KL, Goedde D, Ottaviano L, Dirksen U, et al. (2007) Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J Cancer Res Clin Oncol 133: 749-759. doi:10.1007/s00432-007-0220-2. PubMed: 17530287.
44. Viana-Pereira M, Almeida I, Sousa S, Mahler-Araújo B, Seruca R, et al. (2009) Analysis of microsatellite instability in medulloblastoma. Neuro Oncol 11: 458-467. doi:10.1215/15228517-2008-115. PubMed: 19179424.
45. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, et al. (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15: 4622-4629. doi:10.1158/1078-0432.CCR-08-3012. PubMed: 19584161.
46. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, et al. (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13: 2038-2045. doi:10.1158/1078-0432.CCR-06-2149. PubMed: 17404084.
47. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, et al. (2008) Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 14: 4859-4868. doi:10.1158/1078-0432.CCR-07-4807. PubMed: 18676759.
48. Stark AM, Doukas A, Hugo HH, Mehdorn HM, (2010) The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 32: 816-820. doi:10.1179/016164110X12645013515052. PubMed: 20223108.
49. Laperriere N, Zuraw L, Cairncross G, Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site G, (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64: 259-273.
50. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. PubMed: 15758009.
51. DeAngelis LM, (2009) Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol 27: 5861-5862. doi:10.1200/JCO.2009.24.5985. PubMed: 19901101.
52. Shahi A, Lee JH, Kang Y, Lee SH, Hyun JW, et al. (2011) Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair. Nucleic Acids Res 39: 2130-2143. doi:10.1093/nar/gkq1095. PubMed: 21075794.